Adagio Medical Reports Third Quarter 2026 Results
Recent Business Highlights:
-
Ultra-Low temperature ablation (“ULTA”) featured in four podium presentations at the VT Symposium 2026 held
October 9-10 inNew York , with topics spanning clinical experience, comparative preclinical research and insights from FULCRUM-VT, with particular physician interest centered on the next-generation vCLAS Ultra catheter’s handling, streamlined workflow, and ability to create time efficient deep wide footprint lesions with predictable dimensions
-
Highlighted the first patient treated in the Investigational Device Exemption (“IDE”) sub-study evaluating the Company’s next-generation vCLAS™ Ultra System for Ventricular Tachycardia, which was completed at Banner –
University Medical Center Phoenix , kicking off enrollment across multiple sites to advance the faster, improved ULTA catheter for the broadest population of ventricular tachycardia (“VT”) patients
- Announced that the Company’s Board of Directors initiated a formal process to explore strategic alternatives focused on maximizing shareholder value
-
Treated a total of 22 patients to date with the Company’s vCLAS™ Ultra System in
the United States andCanada , including 19 patients enrolled in the FULCRUM-VT IDE sub-study and 3 compassionate use cases
“The third quarter was defined by progress in the clinical and regulatory programs that we believe are the foundation for the value of Adagio and our ULTA platform. Our PMA application for the vCLAS Ventricular Ablation System remains under FDA review, and we initiated the vCLAS Ultra IDE study, which builds on the FULCRUM-VT results with a faster, more maneuverable next-generation catheter. We were also pleased to see ULTA featured in several podium presentations at the recent VT Symposium, reinforcing the clinical differentiation of a purpose-built, all-endocardial approach to VT,” said
Third Quarter 2026 Financial Results
Cost of revenue was nil for the three months ended
Research and development expenses were
Selling, general and administrative expenses were
Net income for the three months ended
Weighted-average shares of common stock outstanding for the three months ended
Reverse Stock Split
On
About
Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low temperature ablation (“ULTA”, formerly known as ULTC) technology. ULTA is designed to create large footprint, titratable lesions extending through the depth of both diseased and healthy cardiac tissue, all through an endocardial approach. The Company is currently focused on the treatment of ventricular arrhythmias with its purpose-built vCLAS Ventricular Ablation System, which is CE Marked, and in
About FULCRUM VT
FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label, single-arm trial, which has fully enrolled 209 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory VT in accordance with current treatment guidelines. FULCRUM-VT 6-month primary chronic effectiveness was defined as freedom from sustained monomorphic VT lasting longer than 30 seconds or VT requiring appropriate ICD device therapy, in the absence of new or increase in antiarrhythmic drug therapy beyond previously failed dose.
The FDA has granted Investigational Device Exemption (IDE) approval to expand the Company’s FULCRUM-VT trial to evaluate the safety and effectiveness of the Company’s next-generation vCLAS Ultra catheter for the treatment of Sustained Monomorphic Ventricular Tachycardia (SMVT).
Adagio’s vCLAS™ Ventricular Ablation System is commercially available for the treatment of monomorphic VT in Europe and select other geographies but is limited to investigational use in the United States.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning: Adagio’s strategy, future operations, future financial position, and projected expenses; the expected timing and results of Adagio's clinical trials, including the reproducibility of the favorable results initially seen in Adagio’s FULCRUM-VT pivotal data and the evaluation of the vCLAS Ultra catheter under the expanded IDE approval; the potential for ULTA technology to address unmet needs in the treatment of VT, including across both ischemic and non-ischemic cardiomyopathy substrates; the potential for FDA approval of Adagio’s product candidates, including the PMA application for the vCLAS Ventricular Ablation System; Adagio’s pursuit of strategic alternatives and the entry into or completion of any strategic alternative transaction; and Adagio’s ability to regain compliance with Nasdaq’s continued listing requirements, including the Minimum Bid Price Requirement. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Adagio’s business are described in detail in Adagio’s Securities and Exchange Commission (“SEC”) filings, including in its Annual Report on Form 10-K for the full-year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that Adagio makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Adagio disclaims any obligation to update these statements except as may be required by law.
1 Results have been adjusted to reflect the one-for-thirty (1-for-30) reverse stock split effected in November 2026.
| Adagio |
||||||
| Condensed Consolidated Balance Sheets | ||||||
| (in thousands) | ||||||
|
|
|
|||||
|
2026 |
2025 |
|||||
| (Unaudited) | (Audited) | |||||
| Cash and cash equivalents |
$ |
3,095 |
$ |
17,105 |
||
| Total assets |
|
29,860 |
|
43,253 |
||
| Total liabilities |
|
11,497 |
|
30,851 |
||
| Total stockholders' equity |
|
18,363 |
|
12,402 |
||
| Adagio |
||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) | ||||||||
| (in thousands, except share and per share data) | ||||||||
| (unaudited) | ||||||||
| Three Months Ended | ||||||||
|
2026 |
2025 |
|||||||
| Revenue |
$ |
- |
|
$ |
- |
|
||
| Cost of revenue and operating expenses: | ||||||||
| Cost of revenue |
|
- |
|
$ |
31 |
|
||
| Research and development |
|
1,799 |
|
|
2,774 |
|
||
| Selling, general, and administrative |
|
2,572 |
|
|
2,916 |
|
||
| Total cost of revenue and operating expenses |
$ |
4,371 |
|
$ |
5,721 |
|
||
| Loss from Operations |
$ |
(4,371 |
) |
$ |
(5,721 |
) |
||
| Other Income (expense) | ||||||||
| Convertible notes fair value adjustment |
|
22,950 |
|
|
(3,508 |
) |
||
| Warrant liabilities fair value adjustment |
|
66 |
|
|
(231 |
) |
||
| Interest expense |
|
(843 |
) |
|
(749 |
) |
||
| Interest income |
|
40 |
|
|
79 |
|
||
| Other income (expense), net |
|
(2 |
) |
|
12 |
|
||
| Total Other Income (expense), net |
$ |
22,211 |
|
$ |
(4,397 |
) |
||
| Net income (loss) |
$ |
17,840 |
|
$ |
(10,118 |
) |
||
| Other comprehensive income (loss): | ||||||||
| Foreign currency translation adjustment |
$ |
4 |
|
$ |
4 |
|
||
| Comprehensive income (loss) |
$ |
17,844 |
|
|
(10,114 |
) |
||
| Basic net income (loss) per share |
$ |
2.40 |
|
$ |
(19.73 |
) |
||
| Diluted net income (loss) per share |
$ |
(5.13 |
) |
$ |
(19.73 |
) |
||
| Basic weighted average shares outstanding |
|
747,657 |
|
|
512,718 |
|
||
| Diluted weighted average shares outstanding |
|
833,254 |
|
|
512,718 |
|
||
View source version on businesswire.com: https://www.businesswire.com/news/home/20261116254562/en/
Chief Business Officer
dkaster@adagiomedical.com
Source: